1 not yet recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Abdullah Kars: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes Teplizumab, Intralymphatic Insulin Immunotherapy (ILIT) - Type 1 Diabetes Mellitus (T1DM), Type 1 Diabetes Mellitus | Phase 1 | Not yet recruiting | Abdullah Kars | 60 | 2027-01-01 | 2026-05-27 |
teplizumab (1)
Turkey (Türkiye) (1)